Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01827371 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 435
- Enrollment target
NCT01827371 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 435 participants.
The verdict
NCT01827371, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 435 participants
- Enrollment target
Study Summary
Imvamune (licensed name of MVA being developed as a smallpox vaccine) has been tested in over 2,000 individuals and is on path for licensure. This study will be a Phase II to evaluate three different immunization schedules and two different modes of delivery. The study will look at condensed schedules. Study will randomize subjects to one of four arms.
Interventions
- BIOLOGICAL MVA Smallpox Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 435 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01827371
The ClinicalTrials.gov registry entry for NCT01827371 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 435 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MVA Smallpox Vaccine is the first listed.
NCT01827371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01827371 about?
NCT01827371 is a clinical study titled "Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®". Imvamune (licensed name of MVA being developed as a smallpox vaccine) has been tested in over 2,000 individuals and is on path for licensure. This study will be a Phase II to evaluate three different immunization schedules and two different modes of delivery. The study will look at condensed schedul...
What is the current status of trial NCT01827371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 435 participants. The study started on 2013-06. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01827371?
The interventions under investigation include: MVA Smallpox Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01827371?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.